Company intelligence
CACLP
China International In Vitro Diagnostic Expo by CACLP
About CACLP
Debuted in 1991, China International In Vitro Diagnostic Expo by CACLP, is well established as one of the largest exhibitions in the in vitro diagnostic industry worldwide. China IVD Supply Chain Expo, successfully launched since 2021, further expand the product sectors from upstream to downstream. The great number of high-level academic and educational programs taking place concurrently onsite and year-round promotional solutions make CACLP one of the most important platforms for global IVD players. Every year, CACLP brings together over 40,000 professionals including entrepreneurs, scholars, users and thought leaders in the clinical laboratory industry around the globe to exchange the latest developments in the industry, enhance the partnerships and shape the future of IVD industry all together. CACLP 2025 looks forward to welcoming IVD professionals from around the globe.
Verified activity
Signals from CACLP
7 published signals
Products & Services
CACLP reported that China's first BCI product for cognitive impairment auxiliary diagnosis was approved.
Reported by CACLP
Products & Services
CACLP noted that Yingsheng Bio and Sinopharm Group Med-Tech partnered on high-end mass spectrometry.
Reported by CACLP
Partnerships
CACLP noted that Yeasen Biotechnology and MGI Tech entered a strategic partnership on long-read sequencing.
Reported by CACLP
Products & Services
CACLP reported that Wantai BioPharm launched an ISO 15189 solution for blood centers.
Reported by CACLP
Products & Services
CACLP reported that Mirxes' FITRAPID received Singapore HSA approval to expand into the at-home B2C testing market.
Reported by CACLP
Research & Knowledge
CACLP published a new study introducing DN/Au@ZIF-8, a Zn²⁺-activated nanoplatform that enhances photothermal–gene therapy through a self-amplifying therapeutic cascade.
Reported by CACLP
Legal & Regulatory
CACLP notes that the National Health Commission, the National Administration of Traditional Chinese Medicine, and the National Disease Control and Prevention Administration issued a circular outlining measures to further deepen and expand family doctor contract services.
Reported by CACLP